These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21741464)

  • 1. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study.
    Marra M; Salzano G; Leonetti C; Porru M; Franco R; Zappavigna S; Liguori G; Botti G; Chieffi P; Lamberti M; Vitale G; Abbruzzese A; La Rotonda MI; De Rosa G; Caraglia M
    Biotechnol Adv; 2012; 30(1):302-9. PubMed ID: 21741464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.
    Salzano G; Marra M; Porru M; Zappavigna S; Abbruzzese A; La Rotonda MI; Leonetti C; Caraglia M; De Rosa G
    Int J Pharm; 2011 Jan; 403(1-2):292-7. PubMed ID: 21055454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique.
    Schiraldi C; Zappavigna S; D' Agostino A; Porto S; Gaito O; Lusa S; Lamberti M; De Rosa M; De Rosa G; Caraglia M
    Cancer Biol Ther; 2014; 15(11):1524-32. PubMed ID: 25482949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes.
    Marra M; Salzano G; Leonetti C; Tassone P; Scarsella M; Zappavigna S; Calimeri T; Franco R; Liguori G; Cigliana G; Ascani R; La Rotonda MI; Abbruzzese A; Tagliaferri P; Caraglia M; De Rosa G
    Nanomedicine; 2011 Dec; 7(6):955-64. PubMed ID: 21453789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stealth liposomes encapsulating zoledronic acid: a new opportunity to treat neuropathic pain.
    Caraglia M; Luongo L; Salzano G; Zappavigna S; Marra M; Guida F; Lusa S; Giordano C; De Novellis V; Rossi F; Abbruzzese Saccardi A; De Rosa G; Maione S
    Mol Pharm; 2013 Mar; 10(3):1111-8. PubMed ID: 23327778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.
    Porru M; Zappavigna S; Salzano G; Luce A; Stoppacciaro A; Balestrieri ML; Artuso S; Lusa S; De Rosa G; Leonetti C; Caraglia M
    Oncotarget; 2014 Nov; 5(21):10446-59. PubMed ID: 25431953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity.
    Shmeeda H; Amitay Y; Tzemach D; Gorin J; Gabizon A
    J Control Release; 2013 May; 167(3):265-75. PubMed ID: 23419948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transferrin-Targeted Nanoparticles Containing Zoledronic Acid as a Potential Tool to Inhibit Glioblastoma Growth.
    Salzano G; Zappavigna S; Luce A; D'Onofrio N; Balestrieri ML; Grimaldi A; Lusa S; Ingrosso D; Artuso S; Porru M; Leonetti C; Caraglia M; De Rosa G
    J Biomed Nanotechnol; 2016 Apr; 12(4):811-30. PubMed ID: 27301207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel.
    Ramanlal Chaudhari K; Kumar A; Megraj Khandelwal VK; Ukawala M; Manjappa AS; Mishra AK; Monkkonen J; Ramachandra Murthy RS
    J Control Release; 2012 Mar; 158(3):470-8. PubMed ID: 22146683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of antitumor effect of zoledronic acid entrapped in folate-linked liposome for targeting to tumor-associated macrophages.
    Hattori Y; Yamashita J; Sakaida C; Kawano K; Yonemochi E
    J Liposome Res; 2015; 25(2):131-40. PubMed ID: 25203609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer.
    Hashimoto K; Masumori N; Tanaka T; Maeda T; Kobayashi K; Kitamura H; Hirata K; Tsukamoto T
    Prostate; 2013 Apr; 73(5):500-11. PubMed ID: 22996996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
    Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
    J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells.
    Shmeeda H; Amitay Y; Gorin J; Tzemach D; Mak L; Ogorka J; Kumar S; Zhang JA; Gabizon A
    J Control Release; 2010 Aug; 146(1):76-83. PubMed ID: 20462513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.
    Clyburn RD; Reid P; Evans CA; Lefley DV; Holen I
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):969-78. PubMed ID: 19730863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
    Rogers TL; Wind N; Hughes R; Nutter F; Brown HK; Vasiliadou I; Ottewell PD; Holen I
    Cell Oncol (Dordr); 2013 Dec; 36(6):505-14. PubMed ID: 24177992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of the mevalonate pathway in the antiproliferative effect of zoledronate on ACHN renal cell carcinoma cells.
    Fujita M; Tohi M; Sawada K; Yamamoto Y; Nakamura T; Yagami T; Yamamori M; Okamura N
    Oncol Rep; 2012 May; 27(5):1371-6. PubMed ID: 22322451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway.
    Wilson C; Ottewell P; Coleman RE; Holen I
    BMC Cancer; 2015 Feb; 15():55. PubMed ID: 25884855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.
    Au KM; Satterlee A; Min Y; Tian X; Kim YS; Caster JM; Zhang L; Zhang T; Huang L; Wang AZ
    Biomaterials; 2016 Mar; 82():178-93. PubMed ID: 26763733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
    Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
    Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.